Utility of interval kidney biopsy in ANCA-associated vasculitis.

Rheumatology (Oxford)

University of Edinburgh/British Heart Foundation Centre of Research Excellence, Centre for Cardiovascular Science, The Queen's Medical Research Institute.

Published: May 2022

AI Article Synopsis

  • The study investigates the use of interval kidney biopsies in patients with ANCA-associated vasculitis (AAV) to assess kidney involvement over time.
  • Out of 57 patients who had interval biopsies, a significant number were found to be in clinical remission despite prior suspicions of active disease, indicating that clinician assessments can be misleading.
  • The findings suggest that interval biopsies may offer more accurate prognostic information and guide treatment adjustments more effectively than initial biopsies, highlighting the need for their inclusion in future clinical strategies for AAV management.

Article Abstract

Objectives: ANCA-associated vasculitis (AAV) is a rare autoimmune disorder that commonly involves the kidney. Early identification of kidney involvement, assessing treatment-response and predicting outcome are important clinical challenges. Here, we assessed the potential utility of interval kidney biopsy in AAV.

Methods: In a tertiary referral centre with a dedicated vasculitis service, we identified patients with AAV who had undergone interval kidney biopsy, defined as a repeat kidney biopsy (following an initial biopsy showing active AAV) undertaken to determine the histological response in the kidney following induction immunosuppression. We analysed biochemical, histological and outcome data, including times to kidney failure and death for all patients.

Results: We identified 57 patients with AAV who underwent at least one interval kidney biopsy (59 interval biopsies in total; median time to interval biopsy ∼130 days). Of the 59 interval biopsies performed, 24 (41%) patients had clinically suspected active disease at time of biopsy which was confirmed histologically in only 42% of cases; 35 (59%) patients were in clinical disease-remission, and this was correct in 97% of cases. The clinician's impression was incorrect in one in four patients. Hematuria at interval biopsy did not correlate with histological activity. Interval biopsy showed fewer acute lesions and more chronic damage compared with initial biopsy and led to immunosuppressive treatment-change in 75% (44/59) of patients. Clinical risk prediction tools tended to operate better using interval biopsy data.

Conclusion: Interval kidney biopsy is useful for determining treatment-response and subsequent disease management in AAV. It may provide better prognostic information than initial kidney biopsy and should be considered for inclusion into future clinical trials and treatment protocols for patients with AAV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071515PMC
http://dx.doi.org/10.1093/rheumatology/keab695DOI Listing

Publication Analysis

Top Keywords

kidney biopsy
28
interval kidney
20
interval biopsy
16
biopsy
14
patients aav
12
kidney
11
interval
10
utility interval
8
anca-associated vasculitis
8
identified patients
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!